文献速递脊柱关节炎

糖皮质激素在脊柱关节炎中的应用:系统综述与真实世界分析

Glucocorticoids in spondyloarthritis-systematic review and real-world analysis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该系统综述检索了PubMed和EMBASE,纳入14项全身性糖皮质激素研究(364例)和10项局部注射研究(560例)。两项安慰剂对照RCT汇总显示,大剂量口服泼尼松龙(±逐渐减量)使BASDAI 50达成率提高4.2倍(95%CI:1.5,11.5),ASAS 20达成率提高2倍(95%CI:1.1,3.64)。关节内注射6个月持续应答率为51.5-90%,附着点注射可减轻疼痛并改善超声参数,未见死亡或重大不良事件。

要点

  • 大剂量全身性糖皮质激素短期(≤6个月)治疗SpA有良好疗效证据。
  • 关节内注射6个月持续应答率为51.5-90%,附着点注射安全有效。
  • 全身和局部糖皮质激素研究中均无死亡或重大不良事件报告。

核心结论

  • 关于SpA中全身性或局部注射糖皮质激素的研究有限,但大剂量全身性糖皮质激素短期(≤6个月)使用有良好疗效证据。
  • 关节内注射和附着点注射似乎安全有效。

研究设计与样本

  • 系统文献综述检索PubMed(Medline)和EMBASE,纳入报告糖皮质激素疗效的RCT、非随机干预研究和非随机观察性研究,要求患者数≥5。
  • 共纳入14项全身性糖皮质激素研究(364例患者),包括两项口服泼尼松龙RCT。
  • 共纳入10项局部糖皮质激素研究(560例患者),局部注射包括关节内和附着点注射,排除骶髂关节注射。

主要发现

  • 汇总两项安慰剂对照RCT(≤24周)数据,大剂量口服泼尼松龙(±逐渐减量)组BASDAI 50达成率为安慰剂的4.2倍(95%CI:1.5,11.5)。
  • 同一汇总分析中,大剂量口服泼尼松龙(±逐渐减量)组ASAS 20达成率为安慰剂的2倍(95%CI:1.1,3.64)。
  • 脉冲式糖皮质激素治疗带来显著改善,持续数周至数月。
  • 关节内注射在6个月时使51.5-90%的关节获得持续应答。
  • 附着点注射可减轻疼痛并改善超声参数。

关键数值与推荐

  • 全身性糖皮质激素研究共14项、364例患者,其中两项为口服泼尼松龙RCT。
  • 局部糖皮质激素研究共10项、560例患者。
  • BASDAI 50达成率比较的OR为4.2(95%CI:1.5,11.5),ASAS 20达成率比较的OR为2(95%CI:1.1,3.64)。
  • 关节内注射6个月持续应答率为51.5-90%。

临床怎么用

  • 对于SpA患者,可考虑短期(≤6个月)使用大剂量全身性糖皮质激素以快速控制病情。
  • 关节内注射和附着点注射可作为安全有效的局部治疗选择。

局限性

  • 关于SpA中全身性或局部注射糖皮质激素的研究数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to identify and summarize the efficacy and safety of systemic glucocorticoids (GCs) and local injections of GC in SpA. METHODS: PubMed (Medline) and EMBASE were searched with pre-defined keywords for relevant articles in English reporting randomized controlled trials (RCTs), non-randomized interventional studies and non-randomized observational studies of the efficacy of GC in SpA, with five or more patients, for inclusion in a systematic literature review. Local injections of GC included IA and entheseal injections, but excluded SI joint injections. RESULTS: Out of 9657 records identified, there were 14 studies on the use of systemic GCs in SpA (364 patients), including two RCTs of oral prednisolone. On pooling data from two placebo-controlled RCTs (≤24 weeks), BASDAI 50 was 4.2 times more likely (95% CI: 1.5, 11.5) and Ankylosing Spondylitis Assessment Group (ASAS) 20 was twice more likely (95% CI: 1.1, 3.64) to occur in patients on high-dose oral prednisolone (± taper). Pulsed GCs led to dramatic improvements that lasted a few weeks to a few months. There were no deaths or major adverse events. There were 10 studies (560 patients) on local GCs in SpA. IA injection was effective in achieving a sustained response in 51.5-90% of joints at 6 months. Entheseal injections led to reduced pain and improved US parameters. CONCLUSION: There were limited studies on either systemic or local injections of GCs in SpA. However, there was good evidence of efficacy with the use of high-dose systemic GCs in the short term (≤6 months) in SpA. Both IA and entheseal injections seemed safe and effective.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Dhir V, Mishra D, Samanta J, et al. Glucocorticoids in spondyloarthritis-systematic review and real-world analysis. Rheumatology (Oxford). 2021. PMID: 33748829. doi:10.1093/rheumatology/keab275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。